|
The usual starting dose of MICARDIS tablets is 40 mg once a day, but dosage
must be individualized. Blood pressure response is dose-related over the range
of 20 mg to 80 mg. Patients with depletion of intravascular volume should have
the condition corrected or MICARDIS tablets should be initiated under close
medical supervision. MICARDIS tablets should be used with caution in patients
with biliary obstructive disorders, hepatic insufficiency, or impaired renal
function.
The antihypertensive effect is apparent after the first dose and maximal
reduction is generally attained after 4 weeks. When additional blood pressure
reduction is required, you may need to take MICARDIS HCT, which contains the thiazide
diuretic hydrochlorothiazide. Hydrochlorothiazide is effective in doses of 12.5
mg to 50 mg once daily. To minimize side effects, it is usually
appropriate to begin combination therapy only after a patient has failed to
achieve the desired effect with monotherapy.
MICARDIS HCT is not indicated for initial therapy.
MICARDIS and MICARDIS HCT tablets may be administered with other antihypertensive agents and may be administered with or without food.
Selected important cautionary information
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted (e.g., those receiving high doses of diuretics), symptomatic hypotension may occur after initiation of MICARDIS therapy. This condition should be corrected prior to administration of MICARDIS and treatment should start under close medical supervision.
Patients with billary obstructive disorders or hepatic insufficiency should have treatment started under close medical supervision.
|
USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS and MICARDIS HCT Tablets should be discontinued as soon as possible (see WARNINGS, Fetal/Neonatal Morbidity and Mortality).
|
|
| 
